Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” ...